KR950704309A - 벤젠융합된 하이드록시 치환-사이클로알킬 및 헤테로사이클릭 고리 화합물의 설폰아미드 유도체(sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds) - Google Patents

벤젠융합된 하이드록시 치환-사이클로알킬 및 헤테로사이클릭 고리 화합물의 설폰아미드 유도체(sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds)

Info

Publication number
KR950704309A
KR950704309A KR1019950701525A KR19950701525A KR950704309A KR 950704309 A KR950704309 A KR 950704309A KR 1019950701525 A KR1019950701525 A KR 1019950701525A KR 19950701525 A KR19950701525 A KR 19950701525A KR 950704309 A KR950704309 A KR 950704309A
Authority
KR
South Korea
Prior art keywords
cis
ylmethoxy
ylmethyl
trifluoromethanesulfonamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019950701525A
Other languages
English (en)
Korean (ko)
Inventor
앤소니 마페트
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR950704309A publication Critical patent/KR950704309A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019950701525A 1992-10-21 1993-09-30 벤젠융합된 하이드록시 치환-사이클로알킬 및 헤테로사이클릭 고리 화합물의 설폰아미드 유도체(sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds) Ceased KR950704309A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96433792A 1992-10-21 1992-10-21
US07/964,337 1992-10-21
PCT/US1993/009171 WO1994008996A1 (en) 1992-10-21 1993-09-30 Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds

Publications (1)

Publication Number Publication Date
KR950704309A true KR950704309A (ko) 1995-11-17

Family

ID=25508435

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701525A Ceased KR950704309A (ko) 1992-10-21 1993-09-30 벤젠융합된 하이드록시 치환-사이클로알킬 및 헤테로사이클릭 고리 화합물의 설폰아미드 유도체(sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds)

Country Status (23)

Country Link
US (1) US5641789A (enExample)
EP (1) EP0665842A1 (enExample)
JP (1) JPH07508534A (enExample)
KR (1) KR950704309A (enExample)
CN (1) CN1090282A (enExample)
AP (1) AP9300578A0 (enExample)
AU (1) AU5536794A (enExample)
BR (1) BR9307277A (enExample)
CA (1) CA2146261A1 (enExample)
CZ (1) CZ100095A3 (enExample)
FI (1) FI934625A7 (enExample)
HR (1) HRP931297A2 (enExample)
HU (1) HUT68323A (enExample)
IL (1) IL107294A0 (enExample)
MA (1) MA23009A1 (enExample)
MX (1) MX9306528A (enExample)
NO (1) NO303224B1 (enExample)
PL (1) PL308474A1 (enExample)
RU (1) RU95109929A (enExample)
SI (1) SI9300554A (enExample)
TW (1) TW265335B (enExample)
WO (1) WO1994008996A1 (enExample)
ZA (1) ZA937782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539128A (en) * 1994-11-30 1996-07-23 Pfizer Inc. Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
SK31399A3 (en) * 1996-09-16 2000-05-16 Pfizer Processes and intermediates for preparing substituted chromanol derivatives
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
GB9800039D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Benzyl and benzylidene tetralins and derivatives
RU2182004C1 (ru) * 2001-02-22 2002-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственный препарат для парентерального применения
JP4358515B2 (ja) * 2001-04-10 2009-11-04 タカラバイオ株式会社 治療剤
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
EP1579010A4 (en) * 2002-10-17 2010-07-21 Decode Genetics Ehf SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND METHODS OF TREATMENT
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same
CN119912349B (zh) * 2023-10-31 2025-11-21 中国石油天然气股份有限公司 一种可降解凝胶用交联剂、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
MX9306528A (es) 1994-06-30
MA23009A1 (fr) 1994-07-01
CN1090282A (zh) 1994-08-03
TW265335B (enExample) 1995-12-11
AU5536794A (en) 1994-05-09
HUT68323A (en) 1995-06-28
AP9300578A0 (en) 1995-04-07
FI934625L (fi) 1994-04-22
EP0665842A1 (en) 1995-08-09
IL107294A0 (en) 1994-01-25
BR9307277A (pt) 1999-05-11
HRP931297A2 (en) 1996-08-31
NO951506L (no) 1995-04-20
CA2146261A1 (en) 1994-04-28
FI934625A0 (fi) 1993-10-20
CZ100095A3 (en) 1995-11-15
SI9300554A (en) 1995-04-30
NO951506D0 (no) 1995-04-20
JPH07508534A (ja) 1995-09-21
ZA937782B (en) 1995-04-20
FI934625A7 (fi) 1994-04-22
US5641789A (en) 1997-06-24
PL308474A1 (en) 1995-08-07
HU9302969D0 (en) 1993-12-28
NO303224B1 (no) 1998-06-15
WO1994008996A1 (en) 1994-04-28
RU95109929A (ru) 1997-03-20

Similar Documents

Publication Publication Date Title
KR930703246A (ko) 항-아테롬성 동맥 경화성 아릴 화합물
DE3873612D1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69100079D1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
BR8403068A (pt) Compostos,processo para sua preparacao,composicoes farmaceuticas e uso dos ditos compostos
FI860089A0 (fi) Naftalinderivat och foerfarande foer deras framstaellning.
HUT68721A (en) Benzofuran and benzizoxazole derivatives, pharmaceutical composition containing said compounds as active agent and process for preparing them
ATE69807T1 (de) Phenoxyessigsaeure-verbindungen, ihre herstellung, pharmazeutische zusammensetzungen und deren verwendung.
ATE143020T1 (de) Aminocarbonylcarbamate verwandt mit physostigmin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
KR870004955A (ko) 다양한 n-치환된 3-피페리딘카복실산 또는 n-치환된 3-피리딘카복실산 및 당해 유도체
BR9403418A (pt) Composto processo para sua preparaçao medicamento uso e método de reduzir os efeitos adversos de danos neurotóxicos a neurônios centrais
BR9400021A (pt) Uso de um composto, compostos, processo para a produção de um éter e composição farmacêutica
HUT36079A (en) Process for preparing naphthaline derivatives and pharmaceutical compositions containing such compounds as active substances
SE8107524L (sv) Heterocykliska foreningar
SE8005686L (sv) Nya halogenvinkamonderivat jemte sett for deras framstellning
FR2440353A1 (fr) Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
ES2051965T3 (es) Derivados heterociclicos condensados de 1,2,3,4-tetrahidroacridina, un procedimiento para su preparacion y su uso como medicamentos.
PT98911A (pt) Processo para a preparacao de 3-(1h-indazol-3-il)-4-piridinaminas, seus intermediarios e composicoes farmaceuticas que os contem
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
ES8106517A1 (es) Procedimiento para la preparacion de nuevos derivados de 10-halogen-e-homo-eburnanos.
KR900006287A (ko) 2-[4-(2-피페리디노-에톡시)-벤조일]-벤조산의 측쇄 알킬 에스테르, 이의 제조 방법 및 진경제로서의 이의 용도
ES8504712A1 (es) Un procedimiento para preparar nuevas dihidropiridinas
NO164024C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive enantiomerer av substituerte fenylazacykloalkaner.
KR910004593A (ko) N-하이드록시-디벤즈[b,e]옥세핀-알킬아민 및-알카노산 아미드, 관련된 헤테로 사이클릭 동족체, 이들의 제조방법 및 이들의 약제로서의 용도
FI834792A0 (fi) Foerfarande foer framstaellning av aminoetoxibensylalkohol-derivat
PT89054A (pt) Processo para a preparacao de acido n-(bifenilmetil)-3-hidroxi-glutaramico e seus derivados como agentes hipocolesterolemicos

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 19950420

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950420

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980507

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I